We are interested in the type I interferon pathway and its role in protecting the lungs from respiratory viruses. Individuals with chronic lung disease are highly susceptible to viral infections and display deficient antiviral immune responses. We are combining human viral challenge studies with functional experiments in cellular and mouse models to understand the mechanisms that underlie these defects, with the long term aim of driving development of new therapies to restore antiviral function in susceptible individuals.